Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors
{{output}}
KRASG12C has been identified as a potential target in the treatment of solid tumors. One of the most often transformed proteins in human cancers is the small Kirsten rat sarcoma homolog (KRAS) subunit of GTPase, which is typically the oncogene driver. KRASG12C... ...
